Details of the Drug

General Information of Drug (ID: DMGNYIH)

Drug Name

Retigabine

Synonyms

Ezogabine; Potiga; Trobalt; Retigabine [USAN]; D 20443; D 23129; ADD-230001; D-20443; D-23129; GKE-841; KE-0201; Ethyl 2-amino-4-((p-fluorobenzyl)amino)carbanilate; Ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate; [2-Amino-4-[[(4-fluorophenyl)methyl]amino]phenyl]-carbamate; Ethyl N-(2-amino-4-(4-fluorobenzylamino)phenyl)carbamate hydrochloride; N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester; Ethyl (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)carbamate; N-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester; Carbamic acid, (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)-, ethyl ester

Indication

Disease Entry	ICD 11	Status	REF
Behcet disease	4A62	Approved	[1]
Epilepsy	8A60-8A68	Withdrawn from market	[2]

Therapeutic Class

Anticonvulsants

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

303.33

Topological Polar Surface Area (xlogp)

2.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Clearance: The drug present in the plasma can be removed from the body at the rate of 8.3 mL/min/kg [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 7.5 hours [3]
Metabolism: The drug is metabolized via phase II hepatic N-glucurodination and acetylation [4]
Unbound Fraction: The unbound fraction of drug in plasma is 0.2% [3]
Vd: The volume of distribution (Vd) of drug is 8.7 L/kg [5]

Chemical Identifiers

Formula: C16H18FN3O2
IUPAC Name: ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate
Canonical SMILES: CCOC(=O)NC1=C(C=C(C=C1)NCC2=CC=C(C=C2)F)N
InChI: InChI=1S/C16H18FN3O2/c1-2-22-16(21)20-15-8-7-13(9-14(15)18)19-10-11-3-5-12(17)6-4-11/h3-9,19H,2,10,18H2,1H3,(H,20,21)
InChIKey: PCOBBVZJEWWZFR-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 121892
ChEBI ID: CHEBI:68584
CAS Number: 150812-12-7
DrugBank ID: DB04953
TTD ID: D0X7GL
VARIDT ID: DR00700
INTEDE ID: DR1407
ACDINA ID: D00263

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated potassium channel Kv7 (KCNQ)	TTQ29KF	NOUNIPROTAC	Activator	[2]
Voltage-gated potassium channel Kv7.3 (KCNQ3)	TTIVDM3	KCNQ3_HUMAN	Modulator	[6], [7], [8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 1A1 (CYP1A1)	DE6OQ3W	CP1A1_HUMAN	Substrate	[9]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[10]
UDP-glucuronosyltransferase 1A9 (UGT1A9)	DE85D2P	UD19_HUMAN	Substrate	[9]
UDP-glucuronosyltransferase 1A3 (UGT1A3)	DEF2WXN	UD13_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Behcet disease

ICD Disease Classification

4A62

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Voltage-gated potassium channel Kv7 (KCNQ)	DTT	NO-GeName	6.24E-01	0.11	0.85
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DME	UGT1A1	4.53E-01	4.14E-02	1.83E-01
Cytochrome P450 1A1 (CYP1A1)	DME	CYP1A1	7.84E-01	-1.03E-01	-4.48E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Retigabine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Retigabine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[51]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and Midostaurin.	Acute myeloid leukaemia [2A60]	[52]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and Arn-509.	Acute myeloid leukaemia [2A60]	[53]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and Oliceridine.	Acute pain [MG31]	[54]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Retigabine and Ivabradine.	Angina pectoris [BA40]	[53]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Retigabine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[55]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Retigabine and Levalbuterol.	Asthma [CA23]	[56]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and Eribulin.	Breast cancer [2C60-2C6Y]	[52]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[57]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Retigabine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[58]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[56]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Retigabine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[58]
Levomilnacipran	DMV26S8	Moderate	Antagonize the effect of Retigabine when combined with Levomilnacipran.	Chronic pain [MG30]	[59]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Retigabine and Pasireotide.	Cushing syndrome [5A70]	[52]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and Osilodrostat.	Cushing syndrome [5A70]	[51]
Vilazodone	DM4LECQ	Moderate	Antagonize the effect of Retigabine when combined with Vilazodone.	Depression [6A70-6A7Z]	[59]
Vortioxetine	DM6F1PU	Moderate	Antagonize the effect of Retigabine when combined with Vortioxetine.	Depression [6A70-6A7Z]	[59]
Desvenlafaxine	DMHD4PE	Moderate	Antagonize the effect of Retigabine when combined with Desvenlafaxine.	Depression [6A70-6A7Z]	[59]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Retigabine and Esketamine.	Depression [6A70-6A7Z]	[60]
Deutetrabenazine	DMUPFLI	Moderate	Additive CNS depression effects by the combination of Retigabine and Deutetrabenazine.	Dystonic disorder [8A02]	[61]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and Ingrezza.	Dystonic disorder [8A02]	[62]
Ripretinib	DM958QB	Moderate	Decreased clearance of Retigabine due to the transporter inhibition by Ripretinib.	Gastrointestinal stromal tumour [2B5B]	[60]
Brentuximab vedotin	DMWLC57	Moderate	Decreased clearance of Retigabine due to the transporter inhibition by Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[63]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[64]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[52]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Retigabine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[53]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Retigabine and Crizotinib.	Lung cancer [2C25]	[65]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Retigabine and Ceritinib.	Lung cancer [2C25]	[52]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Retigabine and Osimertinib.	Lung cancer [2C25]	[66]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Retigabine and Selpercatinib.	Lung cancer [2C25]	[67]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Retigabine and Lumefantrine.	Malaria [1F40-1F45]	[60]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[53]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Retigabine and Vemurafenib.	Melanoma [2C30]	[52]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and LGX818.	Melanoma [2C30]	[68]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Retigabine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[69]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Retigabine and Lasmiditan.	Migraine [8A80]	[70]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Retigabine and Panobinostat.	Multiple myeloma [2A83]	[71]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Retigabine and Fingolimod.	Multiple sclerosis [8A40]	[52]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Retigabine and Ozanimod.	Multiple sclerosis [8A40]	[72]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and Romidepsin.	Mycosis fungoides [2B01]	[54]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and Entrectinib.	Non-small cell lung cancer [2C25]	[53]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and Rucaparib.	Ovarian cancer [2C73]	[52]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and Triclabendazole.	Parasitic worm infestation [1F90]	[54]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and Pimavanserin.	Parkinsonism [8A00]	[73]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Retigabine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[74]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Retigabine and Lefamulin.	Pneumonia [CA40]	[51]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and Degarelix.	Prostate cancer [2C82]	[53]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and ABIRATERONE.	Prostate cancer [2C82]	[53]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and Enzalutamide.	Prostate cancer [2C82]	[53]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and Relugolix.	Prostate cancer [2C82]	[53]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Retigabine and Amisulpride.	Schizophrenia [6A20]	[75]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and Asenapine.	Schizophrenia [6A20]	[52]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Retigabine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[52]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Retigabine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[52]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[53]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and Pitolisant.	Somnolence [MG42]	[52]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[52]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Retigabine and Lenvatinib.	Thyroid cancer [2D10]	[52]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Retigabine and Cabozantinib.	Thyroid cancer [2D10]	[53]
Betrixaban	DM2C4RF	Moderate	Decreased clearance of Retigabine due to the transporter inhibition by Betrixaban.	Venous thromboembolism [BD72]	[76]
-----------


⏷ Show the Full List of 60 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Caprylic acid	E00017	379	Emulsifying agent; Flavoring agent; Surfactant
FD&C blue no. 2	E00446	2723854	Colorant
Carmellose sodium	E00625	Not Available	Disintegrant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Magnesium stearate	E00208	11177	lubricant
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Soybean lecithin	E00637	Not Available	Other agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Ezogabine 400 mg tablet	400 mg	Oral Tablet	Oral
Ezogabine 50 mg tablet	50 mg	Oral Tablet	Oral
Ezogabine 300 mg tablet	300 mg	Oral Tablet	Oral
Ezogabine 200 mg tablet	200 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Clinical pipeline report, company report or official report of GlaxoSmithKline.
2	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6	The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels. Epilepsia. 2012 Apr;53(4):606-12.
7	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
8	The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia. 2012 Mar;53(3):412-24.
9	Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos. 1999 May;27(5):605-12.
10	N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II. Metabolism. 2006 Jun;55(6):711-21.
11	Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
12	Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
13	Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
14	UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
15	Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
16	Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
17	Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
18	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
19	Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
20	Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
21	Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
22	Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
23	Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
24	Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
25	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
26	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
27	A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
28	Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
29	Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
30	Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
31	Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
32	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
33	UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
34	Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
35	Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
36	Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
37	Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2011 Apr;89(4):524-8.
38	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
39	Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
40	Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
41	The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
42	The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
43	The M-channel blocker linopirdine is an agonist of the capsaicin receptor TRPV1. J Pharmacol Sci. 2010;114(3):332-40.
44	New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep. 2008 Jul;8(4):345-52.
45	Voltage-gated Potassium Channels as Therapeutic Drug Targets
46	Differential tetraethylammonium sensitivity of KCNQ1-4 potassium channels. Br J Pharmacol. 2000 Feb;129(3):413-5.
47	Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
48	The Kv7 potassium channel activator flupirtine affects clinical excitability parameters of myelinated axons in isolated rat sural nerve. J Peripher Nerv Syst. 2010 Mar;15(1):63-72.
49	Treatment with the Kv7 potassium channel activator flupirtine is beneficial in two independent mouse models of pulmonary hypertension. Br J Pharmacol. 2009 August; 157(7): 1241-1249.
50	KV7 channels regulate muscle tone and nonadrenergic noncholinergic relaxation of the rat gastric fundus.Pharmacol Res.2011 Oct;64(4):397-409.
51	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
52	Canadian Pharmacists Association.
53	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
54	Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
55	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
56	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
57	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
58	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
59	Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
60	Cerner Multum, Inc. "Australian Product Information.".
61	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
62	Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
63	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
64	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
65	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
66	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
67	Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
68	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
69	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
70	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
71	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
72	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
73	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
74	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
75	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
76	Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.